10533787

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1604dxj

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

Jagoe

10533787

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:26:56 ON 09 MAR 2009

=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 15:27:10 ON 09 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    8 MAR 2009  HIGHEST RN 1117698-24-4
DICTIONARY FILE UPDATES:   8 MAR 2009  HIGHEST RN 1117698-24-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s strontium ranelate
         77648 STRONTIUM
             2 RANELATE
L1           1 STRONTIUM RANELATE
                 (STRONTIUM(W)RANELATE)

=> s ranelate
L2           2 RANELATE

=> d l2 1-2

L2   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   135459-87-9  REGISTRY
ED   Entered STN:  09 Aug 1991
```

Jagoe

CN 3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2) (CA INDEX NAME)
OTHER NAMES:
CN Distrontium renelate
CN Protelos
CN Protos
CN S 12911
CN S 12911-2
CN **Strontium ranelate**
MF C12 H10 N2 O8 S . 2 Sr
SR CA
LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CIN, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
CRN (135459-90-4)



●2 Sr

173 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
173 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 58194-26-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3-Thiopheneacetic acid, 5-[bis(2-ethoxy-2-oxoethyl)amino]-4-cyano-2-(ethoxycarbonyl)-, ethyl ester (CA INDEX NAME)
OTHER NAMES:
CN **Tetraethyl ranelate**
MF C20 H26 N2 O8 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



10533787

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.11	21.33

FILE 'ADISCTI' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 15:28:07 ON 09 MAR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:28:07 ON 09 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'DISSABS' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'DRUGMONOG2' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:28:07 ON 09 MAR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBAL' ENTERED AT 15:28:07 ON 09 MAR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:28:07 ON 09 MAR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:28:07 ON 09 MAR 2009

Jagoe

10533787

FILE 'IFIPAT' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'IMSDRUGNEWS' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'IMSPRODUCT' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'IPA' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'KOSMET' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'LIFESCI' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'MEDLINE' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'NAPRALERT' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'NLDB' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'NUTRACEUT' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'PASCAL' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'PCTGEN' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'PHARMAML' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'PHIN' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'SCISEARCH' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'TOXCENTER' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'USGENE' ENTERED AT 15:28:07 ON 09 MAR 2009

FILE 'USPATFULL' ENTERED AT 15:28:07 ON 09 MAR 2009

Jagoe

10533787

```
FILE 'USPATOLD' ENTERED AT 15:28:07 ON 09 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:28:07 ON 09 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2 or ranelate
L3        2655 L2 OR RANELATE

=> s protelos or protos
L4        1034 PROTELOS OR PROTOS

=> s l3 or l4
L5        3305 L3 OR L4

=> s pain or ?itis
LEFT TRUNCATION IGNORED FOR FILE 'ADISINSIGHT'
LEFT TRUNCATION IGNORED FOR FILE 'ADISNEWS'
   5 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR FILE 'DDFB'
LEFT TRUNCATION IGNORED FOR FILE 'DGENE'
LEFT TRUNCATION IGNORED FOR FILE 'DRUGB'
LEFT TRUNCATION IGNORED FOR FILE 'DRUGMONOG2'
LEFT TRUNCATION IGNORED FOR FILE 'DRUGU'
  15 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR FILE 'IMSDRUGNEWS'
LEFT TRUNCATION IGNORED FOR FILE 'IPA'
LEFT TRUNCATION IGNORED FOR FILE 'LIFESCI'
LEFT TRUNCATION IGNORED FOR FILE 'NLDB'
LEFT TRUNCATION IGNORED FOR FILE 'NUTRACEUT'
  26 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR FILE 'PCTGEN'
LEFT TRUNCATION IGNORED FOR FILE 'PHARMAML'
  31 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR FILE 'USPATFULL'
LEFT TRUNCATION IGNORED FOR FILE 'USPATFULL'
LEFT TRUNCATION IGNORED FOR FILE 'USPATFULL'
LEFT TRUNCATION IGNORED FOR FILE 'USPATOLD'
LEFT TRUNCATION IGNORED FOR FILE 'USPATOLD'
LEFT TRUNCATION IGNORED FOR FILE 'USPATOLD'
LEFT TRUNCATION IGNORED FOR FILE 'USPAT2'
LEFT TRUNCATION IGNORED FOR FILE 'USPAT2'
LEFT TRUNCATION IGNORED FOR FILE 'USPAT2'
L6     8213771 PAIN OR ?ITIS
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l5 and l6

L7         519 L5 AND L6

=> s l7 and pd<2003
```

Jagoe

```
   5 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
  15 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
  22 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
  28 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
  31 FILES SEARCHED...
L8          17 L7 AND PD<2003

=> dup rem
ENTER L# LIST OR (END):l8
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8
L9           13 DUP REM L8 (4 DUPLICATES REMOVED)

=> d l9 1-13 ibib, kwic

L9   ANSWER 1 OF 13  USPATFULL on STN
ACCESSION NUMBER:       2002:343531  USPATFULL
TITLE:                  Soluble lymphotoxin beta receptor and anti-lymphotoxin
                        receptor and ligand antibodies as therapeutic agents
                        for treatment
INVENTOR(S):            Browning, Jeffrey L., Brookline, MA, UNITED STATES
                        Hochman, Paula S., Newton, MA, UNITED STATES
                        Rennert, Paul D., Millis, MA, UNITED STATES
                        MacKay, Fabienne, Vaucluse, AUSTRALIA

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 20020197254     A1   20021226            <--
                        US 7309492         B2   20071218
APPLICATION INFO.:      US 2001-3211       A1   20011031  (10)
RELATED APPLN. INFO.:   Continuation of Ser. No. US 1999-299139, filed on 23
                        Apr 1999, PENDING

                               NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   WO 1997-US19436    19971024
                        US 1996-29060P     19961025 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   Niki D. Cox, Esq., BIOGEN, INC., 14 Cambridge Center,
                        Cambridge, MA, 02142
NUMBER OF CLAIMS:       50
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     10 Drawing Page(s)
LINE COUNT:             2115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM   .  .  .  which in turn activates mast cells to produce acute
       inflammatory reactions such as those which lead to eczema, asthma and
       rhinitis.
SUMM   .  .  .  immune responses are associated with a number of organ-specific
       and systemic autoimmune conditions such as Systemic Lupus Erythematosus,
```

Wegener's Granulomatosis, **Polyarteritis** Nodosa (PAN), Rapidly Progressive Crescentic **Glomerulonephritis** and Idiopathic Thrombocytopenia Purpura, as well as chronic inflammatory diseases such as the Graves' and Chagas' disease. Humoral immune responses. . .

DETD . . . caused by molecular mimicry. For example, the immune reaction to the lyme disease infectious agent Borrelia burgdorferi leads to an **arthritis**-like disease presumably because saome antigenic epitope on this bacterium resembles a normal joint component. Removal of the FDC-retained lyme bacterium antigen may ameliorate lyme disease induced **arthritis**. Such therapy would also be relevant to other cases of mimicry associated with infectious agents.

DETD . . . Miller et al., J. Exp. Med., 178, pp. 211-222 (1993)). Purified human IgG1 used as a control was purchased from **Protos** Immunoresearch (San Francisco, Calif.). MR1, anti-mouse CD40 ligand antibody, was purchased from Pharmingen (San Diego, Calif.).

DETD . . . include: Myasthenia Gravis, autoimmune hemolytic anemia, Chagas' disease, Grave's disease, idiopathic thrombocytopenia purpura (ITP) Systemic Lupus Erythematosus (SLE), Wegener's Granulomatosis, Poly-**arteritis** Nodosa and Rapidly Progressive Crescentic **Glomerulonephritis**. (From Benjamini, et al. Immunology, A Short Course, (Wiley-Liss, New York 3d ed. (1996)) Although the etiology of SLE is. . . in joint synovial spaces. These complexes activate the complement cascade and attract granulocytes. The subsequent inflammatory reaction is characterized as **glomerulonephritis**, with resulting damage to the kidneys leading to proteinuria and hematuria.

DETD [0174] Lupus **nephritis** has been studied in murine models for decades. Recently, the therapeutic efficacy of a reagent specific for the murine CD40. . .

DETD . . . of activation, and damage from the release of lytic enzymes from their granules results in the destruction of cells. Rheumatic **arthritis** is thought to result from a type III hypersensitivity reaction mediated by immune complexes of antigen (in this case rheumatoid. . .

DETD . . . reagent which inhibits antibody responses to ameliorate a pathologic immunological response is supported in the recent study of mouse lupus **nephritis**. In the latter study, administration of an antibody that blocks the CD40/CD40L pathway was shown inhibit the acceleration of lupus **nephritis** produced upon transfer of cells which induce the production of pathogenic antibodies in vivo, and have a sustained beneficial effect. . .

L9 ANSWER 2 OF 13 USPATFULL on STN

ACCESSION NUMBER:	2002:272935 USPATFULL			
TITLE:	Novel differentiation inducing process of embryonic stem cell to ectodermal cell and its use			
INVENTOR(S):	Sasai, Yoshiki, Kyoto, JAPAN Nishikawa, Shin-Ichi, Kyoto, JAPAN			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020151056	A1	20021017	<--
APPLICATION INFO.:	US 2001-855587	A1	20010516	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 2000-144059		20000516	
	JP 2000-290819		20000925	
	US 2000-257049P		20001220	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			

LEGAL REPRESENTATIVE: FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . so far been established in rat (P. M. Iannaccone et al., Dev. Biol., 163, 288 (1994)), in domestic fowl (B. **Pain** et al., Development, 122, 2339 (1996); U.S. Pat. No. 5,340,740; U.S. Pat. No. 5,656,479)), in pig (M. B. Wheeler, Reprod.. . .
DETD . . . serotonergic neuron marker serotinin (manufactured by Dia Sorin) or an antibody against a noradrenaline neuron marker dopamine β-hydroxylase (manufactured by **PROTOS** Biotech).

L9 ANSWER 3 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2002:243628 USPATFULL
TITLE: Novel purinse
INVENTOR(S): Metcalf, Chester A., III, Boston, MA, UNITED STATES
Weigele, Manfred, Cambridge, MA, UNITED STATES
Sawyer, Tomi K., Southborough, MA, UNITED STATES
Bohacek, Regine, Boston, MA, UNITED STATES
Shakespeare, William C., Framingham, MA, UNITED STATES
Sundaramoorthi, Rajeswari, Watertown, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Dalgarno, David C., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020132819	A1	20020919	<--
APPLICATION INFO.:	US 2000-740653	A1	20001218 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-172510P	19991217 (60)
	US 1999-172161P	19991217 (60)
	US 2000-240788P	20001016 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Karoline Shair, Ph.D., Choate, Hall & Stewart, 53 State Street, Exchange Place, Boston, MA, 02109
NUMBER OF CLAIMS: 195
EXEMPLARY CLAIM: 1
LINE COUNT: 4673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . limited to, Paget's Disease, primary and secondary hyperparathyroidism, humoral hypercalcemia of malignancy, various cancers where resorption is increased, and rheumatoid **arthritis** .
SUMM . . . fast increase in bone mineral content by promoting osteoblast activity. Such examples include peptides from the parathyroid hormone family, strontium **ranelate**, and growth hormone and insulin-like growth response (see, for example, Reginster et al. "Promising New Agents in Osteoporosis," Drugs R. . .

L9 ANSWER 4 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2002:192090 USPATFULL
TITLE: Novel heterocycles

10533787

INVENTOR(S): Weigele, Manfred, Cambridge, MA, UNITED STATES
Luke, George P., Clinton, CT, UNITED STATES
Sawyer, Tomi K., Southborough, MA, UNITED STATES
Bohacek, Regine, Boston, MA, UNITED STATES
Shakespeare, William C., Framingham, MA, UNITED STATES
Sundaramoorthi, Rajeswari, Watertown, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Dalgarno, David C., Brookline, MA, UNITED STATES
Metcalf, Chester A., III, Boston, MA, UNITED STATES
Vu, Chi B., Arlington, MA, UNITED STATES
Kawahata, Noriyuki H., Medford, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020103161	A1	20020801	<--
APPLICATION INFO.:	US 2000-740267	A1	20001218	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-172510P	19991217 (60)
	US 1999-172161P	19991217 (60)
	US 2000-240788P	20001016 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Karoline K.M. Shair, Ph.D., Choate, Hall & Stewart, 53 State Street, Exchange Place, Boston, MA, 02109
NUMBER OF CLAIMS: 111
EXEMPLARY CLAIM: 1
LINE COUNT: 4552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . limited to, Paget's Disease, primary and secondary hyperparathyroidism, humoral hypercalcemia of malignancy, various cancers where resorption is increased, and rheumatoid **arthritis** .

SUMM . . . fast increase in bone mineral content by promoting osteoblast activity. Such examples include peptides from the parathyroid hormone family, strontium **ranelate**, and growth hormone and insulin-like growth response (see, for example, Reginster et al. "Promising New Agents in Osteoporosis," Drugs R. . .

SUMM . . . sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease **pain** at the side of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form,. . .

L9 ANSWER 5 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2002:191593 USPATFULL
TITLE: Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
INVENTOR(S): Tsuji, Takashi, Nagareyama-shi, JAPAN
Tezuka, Katsunari, Yokohama-shi, JAPAN
Hori, Nobuaki, Yokohama-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020102658	A1	20020801	<--
	US 6803039	B2	20041012	
APPLICATION INFO.:	US 2001-859053	A1	20010516	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-147116	20000518
	JP 2001-99508	20010330
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JANIS K. FRASER, PH.D., J.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	108	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	78 Drawing Page(s)	
LINE COUNT:	6932	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . of pharmaceutical compositions according to this invention enables suppression, prevention and/or treatment of, for example, various disorders (for example, rheumatoid **arthritis**, multiple sclerosis, autoimmune **thyroiditis**, allergic contact-type **dermatitis**, chronic inflammatory dermatosis such as lichen planus, systemic lupus erythematosus, insulin-dependent diabetes mellitus, psoriasis, etc.) classified into autoimmune or allergic disorders (particularly autoimmune disease and delayed allergy caused by cellular immunity); arthropathia (for example, rheumatoid **arthritis** (RA) and **osteoarthritis** (OA)), inflammation (e.g., **hepatitis**); graft versus host reaction (GVH reaction); graft versus host disease (GVHD); immune rejection accompanying transplantation (homoplasty or heteroplasty) of a. . . . of cytokines); and disorders possibly caused by the abnormal intestinal immunity (specifically inflammatory intestinal disorders (particularly clone disease and ulcerative **colitis**) and alimentary allergy).

SUMM [0030] The pharmaceutical composition of the present invention can be applied to inflammatory disease for example, inflammation accompanying various **arthritis** (for example, rheumatoid **arthritis**, **osteoarthritis**), pneumonia, **hepatitis** (including viral **hepatitis**), inflammation accompanying infectious diseases, inflammatory bowel diseases, intestinal **enteritis**, **nephritis** (inflammation accompanying glomerular **nephritis**, nephrofibrosis), **gastritis**, **angiitis**, **pancreatitis**, **peritonitis**, **bronchitis**, **myocarditis**, **cerebritis**, inflammation in postischemic reperfusion injury (myocardial ischemic reperfusion injury), inflammation attributed to immune rejection after transplantation of tissue and organ, burn, various skin inflammation (psoriasis, allergic contact-type **dermatitis**, lichen planus which is chronic inflammatory skin disease), inflammation in multiple organ failure, inflammation after operation of PTCA or PTCR, and inflammation accompanying arteriosclerosis, and autoimmune **thyroiditis**.

DETD . . . an active ingredient, it is possible to inhibit or treat and prevent, for example, a variety of diseases (e.g., rheumatoid **arthritis**, multiple sclerosis, autoimmune **thyroiditis**, allergic contact **dermatitis**, lichen planus as a chronic inflammatory skin disease, systemic lupus erythematosus, insulin dependent diabetes mellitus and psoriasis, etc.) classified into autoimmune diseases or allergic diseases (particularly, autoimmune diseases and delayed allergies by cellular immunity); arthropathies (e.g., rheumatoid **arthritis** (RA), **osteoarthritis** (OA)), inflammation (e.g., **hepatitis**); graft versus host reaction (GVH reaction); graft versus host disease (graft versus host

disease; GVHD); immunorejection associated with transplantation (allogenic. . . and diseases that are potentially caused by abnormality in gut immunity (specifically, inflammatory bowel disease (particularly, Crohn's disease and ulcerative **colitis**); and alimentary allergy, etc.

DETD . . . some inflammations for which various steroidal drugs are used as anti-inflammatory drugs, for example, inflammation associated with various arthritides (rheumatoid **arthritis**, **osteoarthritis**, etc.), pneumonia, **hepatitis** (including viral **hepatitis**), inflammation associated with infectious diseases, inflammatory bowel disease, **enteritis**, **nephritis** (glomerular **nephritis**, inflammation associated with kidney fibrosis, **gastritis**, **vasculitis**, **pancreatitis**, **peritonitis**, **bronchitis**, **myocarditis**, **encephalitis**, inflammation associated with ischemia-reperfusion injury (myocaridial ischemia-reperfusion injury, etc.), inflammation associated with immunorejection after transplantation of tissues or organs, scald, various skin inflammations (psoriasis, allergic contact **dermatitis**, lichen planus as a chronic inflammatory skin disease), inflammation associated with multiple organ failure, inflammation after operation of PTCA or PTCR, and inflammation associated with atherosclerosis, autoimmune **thyroiditis**, etc.

DETD [1008] Biotin-labeled anti-human IgG antibody (**Protos**);

DETD [1041] Subsequently, peroxidase-conjugated goat anti-human IgG/κ antibody was added to each well (4,000 times diluted, 100 μl/well, **Protos**), and the plate was incubated at room temperature for 1 hour.

L9 ANSWER 6 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:133863 USPATFULL

TITLE: Purine derivatives

INVENTOR(S): Weigele, Manfred, Cambridge, MA, UNITED STATES
Sawyer, Tomi K., Southborough, MA, UNITED STATES
Bohacek, Regine, Boston, MA, UNITED STATES
Shakespeare, William C., Framingham, MA, UNITED STATES
Sundaramoorthi, Rajeswari, Watertown, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Dalgarno, David C., Brookline, MA, UNITED STATES
Metcalf, Chester A., III, Boston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020068721	A1	20020606	<--
	US 7115589	B2	20061003	
APPLICATION INFO.:	US 2000-740393	A1	20001218 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-740267, filed on 18 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-740653, filed on 18 Dec 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240788P	20001016 (60)
	US 1999-172161P	19991217 (60)
	US 1999-172510P	19991217 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: David L. Berstein, ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234

NUMBER OF CLAIMS: 46

10533787

EXEMPLARY CLAIM: 1
LINE COUNT: 3811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . limited to, Paget's Disease, primary and secondary hyperparathyroidism, humoral hypercalcemia of malignancy, various cancers where resorption is increased, and rheumatoid **arthritis**
.
SUMM . . . fast increase in bone mineral content by promoting osteoblast activity. Such examples include peptides from the parathyroid hormone family, strontium **ranelate**, and growth hormone and insulin-like growth response (see, for example, "Promising New Agents in Osteoporosis", Reginster et al. Drugs R. . .

L9 ANSWER 7 OF 13 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2002177679 EMBASE
TITLE: Strontium **ranelate**: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial.
AUTHOR: Meunier, Pierre J., Dr. (correspondence); Slosman, D.O.; Delmas, P.D.; Sebert, J.L.; Brandi, M.L.; Albanese, C.; Lorenc, R.; Pors-Nielsen, S.; De Vernejoul, M.C.; Roces, A.; Reginster, J.Y.
CORPORATE SOURCE: Hopital Edouard Herriot, 69437 Lyon Cedex 03, France. Meunier@lyon151.inserm.fr
SOURCE: Journal of Clinical Endocrinology and Metabolism, (**2002**) Vol. 87, No. 5, pp. 2060-2066.
Refs: 24
ISSN: 0021-972X CODEN: JCEMAZ
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
003 Endocrinology
033 Orthopedic Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 6 Jun 2002
Last Updated on STN: 6 Jun 2002
TI Strontium **ranelate**: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial.
SO Journal of Clinical Endocrinology and Metabolism, (**2002**) Vol. 87, No. 5, pp. 2060-2066.
Refs: 24
ISSN: 0021-972X CODEN: JCEMAZ
AB The aim of the strontium **ranelate** (SR) for treatment of osteoporosis (STRATOS) trial was to investigate the efficacy and safety of different doses of SR, a. . .
CT Medical Descriptors:
abdominal pain: SI, side effect
adult
aged
alkaline phosphatase blood level
arthralgia: SI, side effect
article
asthenia: SI, side effect
backache: SI, side effect

bone density
bone metabolism
bone mineral
bronchitis: SI, side effect
clinical trial
confidence interval
controlled study
coughing: SI, side effect
dose response
double blind procedure
drug efficacy
drug safety
drug tolerability
dual energy X ray absorptiometry
female
gastrointestinal symptom: SI, side effect
human
hypertension: SI, side effect
lumbar spine
major clinical study
multicenter study
myalgia: SI, side effect
neuralgia: SI, side effect
osteolysis
outcomes research
pharyngitis: SI, side effect
*postmenopause osteoporosis: DT, drug therapy
priority journal
randomized controlled trial
rhinitis: SI, side effect
vertebra fracture
vertebra malformation
vertigo: SI, side effect
alkaline phosphatase: EC, endogenous compound
amino terminal telopeptide: EC, endogenous compound
peptide: EC, endogenous compound
*strontium: AE, adverse drug reaction
*strontium: CT, clinical trial
*strontium: DO, drug dose
*strontium: DT, drug therapy
***strontium ranelate: AE, adverse drug reaction**
***strontium ranelate: CT, clinical trial**
***strontium ranelate: DO, drug dose**
***strontium ranelate: DT, drug therapy**
unclassified drug

RN (alkaline phosphatase) 9001-78-9; (strontium **ranelate**) **135459-87-9**; (strontium) 7440-24-6

L9 ANSWER 8 OF 13 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002221691 EMBASE
TITLE: Treatment of postmenopausal osteoporosis.
AUTHOR: Delmas, Pierre D., Dr. (correspondence)
CORPORATE SOURCE: Claude Bernard University of Lyon, France. delmas@lyon151.inserm.fr
AUTHOR: Delmas, Pierre D., Dr. (correspondence)
CORPORATE SOURCE: INSERM Research Unit 403, Lyon, France. delmas@lyon151.inserm.fr
AUTHOR: Delmas, Pierre D., Dr. (correspondence)
CORPORATE SOURCE: Hopital e Herriot, Pavillon F, 69437 Lyon Cedex 03, France.

10533787

delmas@lyon151.inserm.fr
AUTHOR: Delmas, Pierre D., Dr. (correspondence)
CORPORATE SOURCE: Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France.
delmas@lyon151.inserm.fr
SOURCE: Lancet, (**8 Jun 2002**) Vol. 359, No. 9322, pp. 2018-2026.
Refs: 111
ISSN: 0140-6736 CODEN: LANCAO
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
030 Clinical and Experimental Pharmacology
033 Orthopedic Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jul 2002
Last Updated on STN: 11 Jul 2002
SO Lancet, (**8 Jun 2002**) Vol. 359, No. 9322, pp. 2018-2026.
Refs: 111
ISSN: 0140-6736 CODEN: LANCAO
CT Medical Descriptors:
age
article
bone density
bone mineral
calcium intake
clinical trial
cognitive defect: SI, side effect
diarrhea: SI, side effect
diet
drug efficacy
drug induced disease: SI, side effect
elderly care
esophagitis: SI, side effect
exercise
falling
flushing
*fracture: DT, drug therapy
*fracture: PC, prevention
gastrointestinal disease: SI, side effect
*hip fracture: DT, drug therapy
*hip fracture: PC, prevention
hormone substitution
human
morbidity
nausea:. . .
DO, drug dose
risedronic acid: DT, drug therapy
risedronic acid: PD, pharmacology
selective estrogen receptor modulator: DT, drug therapy
selective estrogen receptor modulator: PD, pharmacology
strontium ranelate: DV, drug development
tamoxifen: DT, drug therapy
tamoxifen: PD, pharmacology
thiazide diuretic agent
tibolone: DT, drug therapy
tibolone: PD, pharmacology
tiludronic acid: DT, drug therapy

tiludronic. . .
RN. . . acid) 40391-99-9, 57248-88-1; (parathyroid hormone) 12584-96-2, 68893-82-3, 9002-64-6; (parathyroid hormone[1-34]) 12583-68-5, 52232-67-4; (raloxifene) 82640-04-8, 84449-90-1; (risedronic acid) 105462-24-6, 122458-82-6; (strontium **ranelate**) **135459-87-9**; (tamoxifen) 10540-29-1; (tibolone) 5630-53-5; (tiludronic acid) 96538-83-9; (vitamin K group) 12001-79-5; (zoledronic acid) 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7

L9 ANSWER 9 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2001:22352 USPATFULL
TITLE: Methods to improve neural outcome
INVENTOR(S): Gluckman, Peter D., Auckland, New Zealand
Williams, Christopher E., Auckland, New Zealand
Guan, Jian, Auckland, New Zealand
PATENT ASSIGNEE(S): Aukland Uniservices Limited, Aukland, New Zealand (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6187906	B1	20010213	<--
APPLICATION INFO.:	US 1999-332868		19990615 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-907918, filed on 11 Aug 1997

	NUMBER	DATE
PRIORITY INFORMATION:	NZ 1998-330684	19980615

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Low, Christopher S. F.
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . insults associated with near-miss drowning, near-miss cot death, carbon monoxide inhalation, ammonia or other gaseous intoxication, cardiac arrest, collapse, coma, **meningitis**, hypoglycaemia and status epilepticus; episodes of cerebral asphyxia associated with coronary bypass surgery; cerebral anoxia or ischemia associated with stroke,. . .
DETD . . . O.sub.2 for 20 minutes, washed with 0.1M PBS (3+5 minutes) and incubated with rabbit polyclonal antisera raised against tyrosine hydroxylase (**Protos** Biotech, USA) diluted 1:500 with 1% goat serum for 48 hours at 4° C. The sections were washed in PBS. . .

L9 ANSWER 10 OF 13 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:388795 SCISEARCH
THE GENUINE ARTICLE: 429BP
TITLE: Incorporation and distribution of strontium in bone
AUTHOR: Dahl S G (Reprint)
CORPORATE SOURCE: Univ Tromso, Fac Med, Dept Pharmacol, N-9037 Tromso, Norway (Reprint)
AUTHOR: Allain P; Marie P J; Mauras Y; Boivin G; Ammann P; Tsouderos Y; Delmas P D; Christiansen C

10533787

CORPORATE SOURCE: CHU Angers, Lab Pharmacol & Toxicol, Angers, France; CNRS, Lariboisiere Hosp, INSERM, U349, Paris, France; Fac Med R Laennec, INSERM, U403, Lyon, France; Univ Geneva, Hop Cantonal, Div Malad Osseuses, Dept Med Interne, CH-1211 Geneva, Switzerland; Inst Rech Int Servier, F-92415 Courbevoie, France; Ctr Clin & Basic Res, Ballerup, Denmark
COUNTRY OF AUTHOR: Norway; France; Switzerland; Denmark
SOURCE: BONE, (**APR 2001**) Vol. 28, No. 4, pp. 446-453. ISSN: 8756-3282.
PUBLISHER: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 77
ENTRY DATE: Entered STN: 25 May 2001
Last Updated on STN: 25 May 2001
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

SO BONE, (**APR 2001**) Vol. 28, No. 4, pp. 446-453. ISSN: 8756-3282.

AB . . . into bone has been examined in rats, monkeys, and humans after oral administration of strontium (either strontium chloride or strontium **ranelate**), After repeated administration for a sufficient period of time (at least 4 weeks in rats), strontium incorporation into bone reaches. . .

STP KeyWords Plus (R): POSTMENOPAUSAL OSTEOPOROSIS; CALCIUM-METABOLISM; MINERAL DENSITY; ILIAC BONE; RATS; FLUORIDE; RESORPTION; **ARTHRITIS**; TURNOVER; SKELETON

L9 ANSWER 11 OF 13 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:550064 BIOSIS
DOCUMENT NUMBER: PREV200100550064
TITLE: Strontium **ranelate** increases cartilage matrix formation.
AUTHOR(S): Henrotin, Y. [Reprint author]; Labasse, A. [Reprint author]; Galais, Ph.; Tsouderos, Y.; Crielaard, J. M. [Reprint author]; Reginster, J. Y. [Reprint author]
CORPORATE SOURCE: Bone and Cartilage Metabolism Research Unit, University Hospital, CHU Sart-Tilman, 4000, Liege, Belgium
SOURCE: Clinical Rheumatology, (**2001**) Vol. 20, No. 5, pp. 416. print.
Meeting Info.: 5th Belgian Congress on Rheumatology. Hasselt, Belgium. September 27-29, 2001.
CODEN: CLRHD6. ISSN: 0770-3198.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Nov 2001
Last Updated on STN: 25 Feb 2002

TI Strontium **ranelate** increases cartilage matrix formation.

SO Clinical Rheumatology, (**2001**) Vol. 20, No. 5, pp. 416. print.
Meeting Info.: 5th Belgian Congress on Rheumatology. Hasselt, Belgium. September 27-29, 2001.
CODEN:. . .

IT . . .
(Movement and Support)

IT Parts, Structures, & Systems of Organisms
cartilage: skeletal system, matrix formation; chondrocytes: skeletal system

Jagoe

IT Diseases
osteoarthritis: joint disease
Osteoarthritis (MeSH)
IT Chemicals & Biochemicals
insulin-like growth factor-I; interleukin-1 beta; proteoglycans: production; stromelysin: activation; strontium **ranelate**: antiarthritic-drug

L9 ANSWER 12 OF 13 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN DUPLICATE 1
ACCESSION NUMBER: 2001:120190 BIOSIS
DOCUMENT NUMBER: PREV200100120190
TITLE: Strontium **ranelate** increases cartilage matrix formation.
AUTHOR(S): Henrotin, Y. [Reprint author]; Labasse, A.; Zheng, S. X.; Galais, Ph.; Tsouderos, Y.; Crielaard, J. M.; Reginster, J. Y.
CORPORATE SOURCE: Bone and Cartilage Metabolism Research Unit Institute of Pathology, C.H.U. Sart-Tilman, Bat B23, B-4000, Liege, Belgium
SOURCE: Journal of Bone and Mineral Research, (**February, 2001**) Vol. 16, No. 2, pp. 299-308. print.
CODEN: JBMREJ. ISSN: 0884-0431.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Mar 2001
Last Updated on STN: 15 Feb 2002
TI Strontium **ranelate** increases cartilage matrix formation.
SO Journal of Bone and Mineral Research, (**February, 2001**) Vol. 16, No. 2, pp. 299-308. print.
CODEN: JBMREJ. ISSN: 0884-0431.
AB Based on previous studies showing that strontium **ranelate** (S12911) modulates bone loss in osteoporosis, it could be hypothesized that this drug also is effective on cartilage degradation in **osteoarthritis** (OA). This was investigated in vitro on normal and OA human chondrocytes treated or not treated with interleukin-1beta (IL-1beta). This. . . in OA cartilage. Chondrocytes were isolated from cartilage by enzymatic digestion and cultured for 24-72 h with 10-4-10-3 M strontium **ranelate**, 10-3 M calcium **ranelate**, or 2.10-3 M SrCl2 with or without IL-1beta or insulin-like growth factor I (IGF-I). Stromelysin activity and stromelysin quantitation were. . . were quantified by labeled sulfate (Na235SO4) incorporation. This method allowed the PG size after exclusion chromatography to be determined. Strontium **ranelate**, calcium **ranelate**, and SrCl2 did not modify stromelysin synthesis even in the presence of IL-1beta. Calcium **ranelate** induced stromelysin activation whereas strontium compounds were ineffective. Strontium **ranelate** and SrCl2 both strongly stimulated PG production suggesting an ionic effect of strontium independent of the organic moiety. Moreover, 10-3 M strontium **ranelate** increased the stimulatory effect of IGF-I (10-9 M) on PG synthesis but did not reverse the inhibitory effect of IL-1beta. Strontium **ranelate** strongly stimulates human cartilage matrix formation in vitro by a direct ionic effect without stimulating the chondroresorption processes. This finding provides a preclinical basis for in vivo testing of strontium **ranelate** in OA.
IT . . .
System (Movement and Support); Pharmacology
IT Parts, Structures, & Systems of Organisms
cartilage: skeletal system; chondrocytes: skeletal system
IT Diseases

osteoarthritis: joint disease
Osteoarthritis (MeSH)
IT Diseases
osteoporosis: bone disease
Osteoporosis (MeSH)
IT Chemicals & Biochemicals
interleukin-1-beta; strontium **ranelate** [S12911]
RN **135459-87-9** (S12911)

L9 ANSWER 13 OF 13 IMSPRODUCT COPYRIGHT 2009 IMSWORLD on STN

SO Drug Launches, (**20 Sep 1999**)
CN Trade Name: **PROTOS**
CN Chemical Name: protoporphyrin IX disodium
TX Hepatic disorders caused **cholecystitis** or gall stones